Last reviewed · How we verify
POMx
POMx is a pomegranate extract-based therapeutic that leverages polyphenolic compounds to exert antioxidant and anti-inflammatory effects.
At a glance
| Generic name | POMx |
|---|---|
| Sponsor | HaEmek Medical Center, Israel |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Pomegranate extract contains high concentrations of punicalagins and other polyphenols that act as free radical scavengers and inhibit pro-inflammatory pathways. The mechanism is thought to involve reduction of oxidative stress and modulation of inflammatory cytokines, potentially benefiting conditions characterized by chronic inflammation or oxidative damage.
Approved indications
Common side effects
Key clinical trials
- Pomegranate Extract and Memory (PHASE2)
- Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance (PHASE2)
- Effects of Phytonutrients on Vascular Health (NA)
- Effects of Pomegranate Extract on Intestinal Flora (NA)
- Cognitive Impact of Pomegranate Polyphenols Following Ischemic Stroke (PHASE2)
- The Impact of Pomegranate Extract on Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study (PHASE2)
- The Effect of Pomegranate on Aging and Inflammation of the Skin (NA)
- A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- POMx CI brief — competitive landscape report
- POMx updates RSS · CI watch RSS
- HaEmek Medical Center, Israel portfolio CI